Abstract
The most characteristic feature of airway inflammation in cystic fibrosis (CF) is the persistent infiltration of massive numbers of neutrophils. Although inflammation is primarily a protective response to injury, it has the potential to cause considerable harm when it is excessive. Recent recognition of the prominent role of inflammation has prompted the investigation of treatments designed to control inflammation in the CF lung. We report a 35-year-old man with abrupt stabilization of his rapidly progressive CF and forced expiratory volume (FEV1) after starting infliximab for his rheumatoid arthritis. This effect was sustained for 8 years while continuing to use twice-monthly infliximab.
This is a preview of subscription content, log in via an institution to check access.
References
Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168(8):918–951. doi:10.1164/rccm.200304-505SO
Brown RK, Kelly FJ (1994) Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 49(8):738–742. doi:10.1136/thx.49.8.738
Barnes PJ, Karin M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336(15):1066–1071. doi:10.1056/NEJM199704103361506
Bonfield TL, Panuska JR, Konstan MW et al (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152(6 Pt 1):2111–2118
Belaaouaj A, McCarthy R, Baumann M, Gao Z, Ley TJ, Abraham SN et al (1998) Mice lacking neutrophil elastase reveal impaired host defense against gram negative bacterial sepsis. Nat Med 4(5):615–618. doi:10.1038/nm0598-615
Antoniu SA (2006) Etanercept for refractory asthma therapy. Expert Opin Investig Drugs 15(10):1279–1281. doi:10.1517/13543784.15.10.1279
Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN (2005) Anti-TNF therapy: where have we got to in 2005? J Autoimmun 25:26–28. doi:10.1016/j.jaut.2005.09.006 Suppl
Tracey KJ, Fong Y, Hesse DG et al (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330(6149):662–664. doi:10.1038/330662a0
Guilbault C, Saeed Z, Downey GP, Radzioch D (2007) Cystic fibrosis mouse models. Am J Respir Cell Mol Biol 36(1):1–7. doi:10.1165/rcmb.2006-0184TR
Auerbach HS, Williams M, Kirkpatrick JA, Colten HR (1985) Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 2(8457):686–688. doi:10.1016/S0140-6736(85)92929-0
Eigen H, Rosenstein BJ, FitzSimmons S, Schidlow DV (1995) A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr 126(4):515–523. doi:10.1016/S0022-3476(95)70343-8
Konstan MW, Byard PJ, Hoppel CL, Davis PB (1995) Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 332(13):848–854. doi:10.1056/NEJM199503303321303
Konstan MW, Schluchter MD, Xue W, Davis PB (2007) Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 176(11):1084–1089. doi:10.1164/rccm.200702-181OC
Chmiel J, Konstan MW (2007) Inflammation and anti-Inflammatory therapies for cystic fibrosis. Clin Chest Med 28(2):331–346. doi:10.1016/j.ccm.2007.02.002
Yarden J, Radojkovic D, De Boeck K et al (2005) Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60(4):320–325. doi:10.1136/thx.2004.025262
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Casserly, B., Donat, W. Stabilization of Lung Function and Clinical Symptoms in a Patient with Cystic Fibrosis (CF) After Institution of Infliximab: A Monoclonal Antibody that Binds Tumor Necrosis Factor alpha. Lung 187, 149–152 (2009). https://doi.org/10.1007/s00408-009-9138-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-009-9138-6